256 related articles for article (PubMed ID: 33125944)
1. Avelumab-cetuximab-radiotherapy versus standards of care in locally advanced squamous-cell carcinoma of the head and neck: The safety phase of a randomised phase III trial GORTEC 2017-01 (REACH).
Tao Y; Aupérin A; Sun X; Sire C; Martin L; Coutte A; Lafond C; Miroir J; Liem X; Rolland F; Even C; Nguyen F; Saada E; Maillard A; Colin-Batailhou N; Thariat J; Guigay J; Bourhis J
Eur J Cancer; 2020 Dec; 141():21-29. PubMed ID: 33125944
[TBL] [Abstract][Full Text] [Related]
2. Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial.
Tao Y; Biau J; Sun XS; Sire C; Martin L; Alfonsi M; Prevost JB; Modesto A; Lafond C; Tourani JM; Miroir J; Kaminsky MC; Coutte A; Liem X; Chautard E; Vauleon E; Drouet F; Ruffier A; Ramee JF; Waksi G; Péchery A; Wanneveich M; Guigay J; Aupérin A; Bourhis J
Ann Oncol; 2023 Jan; 34(1):101-110. PubMed ID: 36522816
[TBL] [Abstract][Full Text] [Related]
3. Immuno-radiotherapy with cetuximab and avelumab for advanced stage head and neck squamous cell carcinoma: Results from a phase-I trial.
Elbers JBW; Al-Mamgani A; Tesseslaar MET; van den Brekel MWM; Lange CAH; van der Wal JE; Verheij M; Zuur CL; de Boer JP
Radiother Oncol; 2020 Jan; 142():79-84. PubMed ID: 31563412
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (XDC-001).
Prawira A; Brana-Garcia I; Spreafico A; Hope A; Waldron J; Razak AR; Chen EX; Jang R; O'Sullivan B; Giuliani M; Bayley A; Cho J; Wang L; Perez-Ordonez B; Weinreb I; Siu LL; Hansen AR
Invest New Drugs; 2016 Oct; 34(5):575-83. PubMed ID: 27289242
[TBL] [Abstract][Full Text] [Related]
5. Docetaxel, cisplatin and 5-FU compared with docetaxel, cisplatin and cetuximab as induction chemotherapy in advanced squamous cell carcinoma of the head and neck: Results of a randomised phase II AGMT trial.
Keil F; Hartl M; Altorjai G; Berghold A; Riedl R; Pecherstorfer M; Mayrbäurl B; De Vries A; Schuster J; Hackl J; Füreder T; Melchardt T; Burian M; Greil R
Eur J Cancer; 2021 Jul; 151():201-210. PubMed ID: 34022697
[TBL] [Abstract][Full Text] [Related]
6. A multicenter phase II trial of paclitaxel, carboplatin, and cetuximab followed by chemoradiotherapy in patients with unresectable locally advanced squamous cell carcinoma of the head and neck.
Enokida T; Ogawa T; Homma A; Okami K; Minami S; Nakanome A; Shimizu Y; Maki D; Ueda Y; Fujisawa T; Motegi A; Ohkoshi A; Taguchi J; Ebisumoto K; Nomura S; Okano S; Tahara M
Cancer Med; 2020 Mar; 9(5):1671-1682. PubMed ID: 31943834
[TBL] [Abstract][Full Text] [Related]
7. Phase II/III Randomized Controlled Trial of Concomitant Hyperfractionated Radiotherapy plus Cetuximab (Anti-EGFR Antibody) or Chemotherapy in Locally Advanced Head and Neck Cancer.
Al-Saleh K; El-Sherify M; Safwat R; Elbasmy A; Shete J; Hussein A; Nazeeh M; Bedair A
Gulf J Oncolog; 2019 May; 1(30):6-12. PubMed ID: 31242976
[TBL] [Abstract][Full Text] [Related]
8. Concurrent cisplatin and dose escalation with intensity-modulated radiotherapy (IMRT) versus conventional radiotherapy for locally advanced head and neck squamous cell carcinomas (HNSCC): GORTEC 2004-01 randomized phase III trial.
Tao Y; Auperin A; Blanchard P; Alfonsi M; Sun XS; Rives M; Pointreau Y; Castelli J; Graff P; Wong Hee Kam S; Thariat J; Veresezan O; Heymann S; Renard-Oldrini S; Lafond C; Cornely A; Casiraghi O; Boisselier P; Lapeyre M; Biau J; Bourhis J
Radiother Oncol; 2020 Sep; 150():18-25. PubMed ID: 32417348
[TBL] [Abstract][Full Text] [Related]
9. A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer.
Patil VM; Noronha V; Joshi A; Agarwal J; Ghosh-Laskar S; Budrukkar A; Murthy V; Gupta T; Mahimkar M; Juvekar S; Arya S; Mahajan A; Agarwal A; Purandare N; Rangarajan V; Balaji A; Chaudhari SV; Banavali S; Kannan S; Bhattacharjee A; D'Cruz AK; Chaturvedi P; Pai PS; Chaukar D; Pantvaidya G; Nair D; Nair S; Deshmukh A; Thiagarajan S; Mathrudev V; Manjrekar A; Dhumal S; Maske K; Bhelekar AS; Nawale K; Chandrasekharan A; Pande N; Goel A; Talreja V; Simha V; Srinivas S; Swami R; Vallathol DH; Dsouza H; Shrirangwar S; Turkar S; Abraham G; Thanky AH; Patel U; Pandey MK; Prabhash K
Cancer; 2019 Sep; 125(18):3184-3197. PubMed ID: 31150120
[TBL] [Abstract][Full Text] [Related]
10. Postoperative chemoradiotherapy and cetuximab for high-risk squamous cell carcinoma of the head and neck: Radiation Therapy Oncology Group RTOG-0234.
Harari PM; Harris J; Kies MS; Myers JN; Jordan RC; Gillison ML; Foote RL; Machtay M; Rotman M; Khuntia D; Straube W; Zhang Q; Ang K
J Clin Oncol; 2014 Aug; 32(23):2486-95. PubMed ID: 25002723
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of cetuximab in combination with cisplatin and radiation in unresectable, locally advanced head and neck squamous cell carcinoma: Eastern cooperative oncology group trial E3303.
Egloff AM; Lee JW; Langer CJ; Quon H; Vaezi A; Grandis JR; Seethala RR; Wang L; Shin DM; Argiris A; Yang D; Mehra R; Ridge JA; Patel UA; Burtness BA; Forastiere AA
Clin Cancer Res; 2014 Oct; 20(19):5041-51. PubMed ID: 25107914
[TBL] [Abstract][Full Text] [Related]
12. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522.
Ang KK; Zhang Q; Rosenthal DI; Nguyen-Tan PF; Sherman EJ; Weber RS; Galvin JM; Bonner JA; Harris J; El-Naggar AK; Gillison ML; Jordan RC; Konski AA; Thorstad WL; Trotti A; Beitler JJ; Garden AS; Spanos WJ; Yom SS; Axelrod RS
J Clin Oncol; 2014 Sep; 32(27):2940-50. PubMed ID: 25154822
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of bevacizumab + cetuximab + cisplatin with concurrent intensity-modulated radiation therapy for patients with stage III/IVB head and neck squamous cell carcinoma.
Fury MG; Xiao H; Sherman EJ; Baxi S; Smith-Marrone S; Schupak K; Gewanter R; Gelblum D; Haque S; Schoder H; Shah JP; Katabi N; Kurtzman R; Lipson B; Cox L; Lee NY; Pfister DG
Head Neck; 2016 Apr; 38 Suppl 1(Suppl 1):E566-70. PubMed ID: 25784616
[TBL] [Abstract][Full Text] [Related]
14. Phase III Randomized Study of Induction Chemotherapy Followed by Definitive Radiotherapy + Cetuximab Versus Chemoradiotherapy in Squamous Cell Carcinoma of Head and Neck: The INTERCEPTOR-GONO Study (NCT00999700).
Merlano MC; Denaro N; Vecchio S; Licitra L; Curcio P; Benasso M; Bagicalupo A; Numico G; Russi E; Corvo' R; Bruzzi P;
Oncology; 2020; 98(11):763-770. PubMed ID: 32629446
[TBL] [Abstract][Full Text] [Related]
15. IMRT with simultaneous integrated boost and concurrent chemotherapy for locoregionally advanced squamous cell carcinoma of the head and neck.
Montejo ME; Shrieve DC; Bentz BG; Hunt JP; Buchman LO; Agarwal N; Hitchcock YJ
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e845-52. PubMed ID: 21167654
[TBL] [Abstract][Full Text] [Related]
16. nab-Paclitaxel and cisplatin followed by cisplatin and radiation (Arm 1) and nab-paclitaxel followed by cetuximab and radiation (Arm 2) for locally advanced head and neck squamous-cell carcinoma: a multicenter, non-randomized phase 2 trial.
Oppelt P; Ley J; Daly M; Rich J; Paniello R; Jackson RS; Pipkorn P; Liu J; Gay H; Palka K; Neupane P; Powell S; Spanos WC; Gitau M; Zevallos J; Thorstad W; Adkins D
Med Oncol; 2021 Mar; 38(4):35. PubMed ID: 33683482
[TBL] [Abstract][Full Text] [Related]
17. Radiochemoimmunotherapy with intensity-modulated concomitant boost: interim analysis of the REACH trial.
Jensen AD; Krauss J; Potthoff K; Simon C; Nikoghosyan AV; Lossner K; Debus J; Münter MW
Radiat Oncol; 2012 Apr; 7():57. PubMed ID: 22472064
[TBL] [Abstract][Full Text] [Related]
18. A Phase 1b Study of Cetuximab and BYL719 (Alpelisib) Concurrent with Intensity Modulated Radiation Therapy in Stage III-IVB Head and Neck Squamous Cell Carcinoma.
Dunn LA; Riaz N; Fury MG; McBride SM; Michel L; Lee NY; Sherman EJ; Baxi SS; Haque SS; Katabi N; Wong RJ; Xiao H; Ho AL; Pfister DG
Int J Radiat Oncol Biol Phys; 2020 Mar; 106(3):564-570. PubMed ID: 31678634
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of dose-escalated cisplatin with concomitant cetuximab and hyperfractionated-accelerated radiotherapy in locally advanced squamous cell carcinoma of the head and neck.
Kuhnt T; Sandner A; Wendt T; Engenhart-Cabillic R; Lammering G; Flentje M; Grabenbauer G; Schreiber A; Pirnasch A; Dunst J
Ann Oncol; 2010 Nov; 21(11):2284-2289. PubMed ID: 20427347
[TBL] [Abstract][Full Text] [Related]
20. Feasibility of 6-month maintenance cetuximab after adjuvant concurrent chemoradiation plus cetuximab in squamous cell carcinoma of the head and neck.
Matuschek C; Bölke E; Belka C; Ganswindt U; Henke M; Stegmaier P; Bamberg M; Welz S; Debus J; Gioules A; Voigt A; Volk G; Ohmann C; Wiegel T; Budach V; Stuschke M; Schipper J; Gerber PA; Budach W
Strahlenther Onkol; 2013 Aug; 189(8):625-31. PubMed ID: 23824104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
